Citations

Clear

390 citation(s) found for "Loftus, E".

Potential Pitfalls When Assessing the Impact of Cytomegalovirus in Inflammatory Bowel Disease
Bruining, David H. , Loftus, Edward V. , McCurdy, Jeffrey D , Loftus, Edward V

Mayo Clinic

Journal of Clinical Gastroenterology | March 9, 2017 | Volume: 53 | Issue: 5 | Pages: 394-395

10.1097/mcg.0000000000000812 | PMID 28277375 Get It

Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells
Roos, Alison , Mathews, Ian T. , Inge, Landon J. , Tuncali, Serdar, Hartman, Lauren, Chow, Donald, Millard, Nghia , Yin, Holly, Kloss, Jean , Loftus, Joseph C. , Winkles, Jeffrey A. , Tran, Nhan L. , Dhruv, Harshil , Berens, Michael E. , Tran, Nhan L

Mayo Clinic

Oncotarget | January 18, 2017 | Volume: 8 | Issue: 7 | Pages: 12234-12246

10.18632/oncotarget.14685 | PMID 28103571 Get It

Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study
Cotter, Thomas G. , Binder, Moritz , Loftus, Edward V. , Abboud, Rami, McNally, Meredythe A., Smyrk, Thomas C. , Tremaine, William J., Sandborn, William J. , Pardi, Darrell S. , Cotter, T G , Binder, Moritz , Loftus, Edward V

Mayo Clinic

Gut | December 13, 2016 | Volume: 67 | Issue: 3 | Pages: 441-446

10.1136/gutjnl-2016-313051 | PMID 27965284 Get It

Objective Microscopic colitis (MC) is a common cause of chronic diarrhoea, often with additional symptoms. No validated instruments exist to assess disease activity in MC, making it difficult to compare efficacy of treatments between clinical trials. We aimed to identify clinical features that independently predicted disease severity and create a Microscopic Colitis Disease Activity Index (MCDAI). Design Patients with MC were prospectively administered a survey assessing their GI symptoms and the IBD Questionnaire (IBDQ). A single investigator also scored a physician global assessment (PGA) of disease severity on a 10-point scale. Multiple linear regression identified which symptoms best predicted the PGA. These symptoms were then combined in a weighted formula to create the MCDAI. The relationship between MCDAI and the IBDQ was investigated. Results Of the 175 patients enrolled, 13 (7.4%) did not complete the survey. The remaining 162 had a median age of 66 years (range, 57–73) and 74% were female. Several clinical features were independently associated with PGA (number of unformed stools daily, presence of nocturnal stools, abdominal pain, weight loss, faecal urgency and faecal incontinence). These parameters were combined to create the MCDAI, which strongly predicted the PGA (R 2 =0.80). A 1-unit decrease in disease activity (ΔMCDAI) was associated with a 9-unit increase in quality of life (ΔIBDQ). Conclusions The MCDAI strongly predicted the PGA and correlated with a validated measure of quality of life. Several symptoms in addition to diarrhoea are associated with disease severity in MC.
PTH-072 Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated with Vedolizumab
Loftus, Edward V. , Sandborn, William J. , James, A. , Xu, Jing , Abhyankar, B, Siegel, Corey A , Panaccione, Remo , Smyth, Michael D.L. , Loftus, Edward V

Mayo Clinic

BSG 2016 | November 23, 2016 | Volume: No volume available | Issue: No issue available | Pages: A254.2-A255

10.1136/gutjnl-2016-312388.478 Get It

PWE-020 Corticosteroid Dose Reduction with Vedolizumab Treatment of Crohn’s Disease
Loftus, Edward V. , Sandborn, W., James, A. , Xu, Jing , Abhyankar, B, Siegel, Corey A , Panaccione, Remo , Smyth, Michael D.L. , Loftus, Edward V

Mayo Clinic

BSG 2016 | November 23, 2016 | Volume: No volume available | Issue: No issue available | Pages: A147.1-A147

10.1136/gutjnl-2016-312388.265 Get It

Development of an index to define overall disease severity in IBD
Whitman, Cynthia B. , Spiegel, Brennan , Feagan, Brian G. , Loftus, Edward V. , D’Haens, Geert , Bernstein, Çharles N. , Gearry, Richard B. , Mantzaris, Gerassimos J. , Sartor, Balfour R., Silverberg, Mark S. , Riddell, Robert H. , O’Morain, Colm, Lakatos, Péter L. , Halfvarson, Jonas , Reinisch, Walter, Rogler, Gerhard , Kruis, Wolfgang , Tysk, Curt , Danese, Silvio , Sandborn, William J. , Gasché, Christoph , Pallone, Francesco, Travis, Simon , Peyrin‐Biroulet, Laurent , Siegel, Corey A , Sands, Bruce E , Panaccione, Remo , Bernstein, Charles Noah , Ng, Siew C. , Κoutroubakis, Ioannis E. , McGovern, Dermot , Halfvarson, Jonas , Schreiber, Stefan , Griffiths, Anne Marie , Moum, Bjørn Allan , Panés, Julián , Colombel, Jean‐Frédéric , Hanauer, Stephen B. , Loftus, Edward V , Danese, Silvio , Peyrin-Biroulet, Laurent , Spiegel, Brennan , Lakatos, Peter L

Mayo Clinic

Gut | October 25, 2016 | Volume: 67 | Issue: 2 | Pages: 244-254

10.1136/gutjnl-2016-312648 | PMID 27780886 Get It

Background and aim Disease activity for Crohn's disease (CD) and UC is typically defined based on symptoms at a moment in time, and ignores the long-term burden of disease. The aims of this study were to select the attributes determining overall disease severity, to rank the importance of and to score these individual attributes for both CD and UC. Methods Using a modified Delphi panel, 14 members of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) selected the most important attributes related to IBD. Eighteen IOIBD members then completed a statistical exercise (conjoint analysis) to create a relative ranking of these attributes. Adjusted utilities were developed by creating proportions for each level within an attribute. Results For CD, 15.8% of overall disease severity was attributed to the presence of mucosal lesions, 10.9% to history of a fistula, 9.7% to history of abscess and 7.4% to history of intestinal resection. For UC, 18.1% of overall disease severity was attributed to mucosal lesions, followed by 14.0% for impact on daily activities, 11.2% C reactive protein and 10.1% for prior experience with biologics. Overall disease severity indices were created on a 100-point scale by applying each attribute's average importance to the adjusted utilities. Conclusions Based on specialist opinion, overall CD severity was associated more with intestinal damage, in contrast to overall UC disease severity, which was more dependent on symptoms and impact on daily life. Once validated, disease severity indices may provide a useful tool for consistent assessment of overall disease severity in patients with IBD.
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
Mace, Thomas A. , Shakya, Reena, Pitarresi, Jason R. , Swanson, Benjamin , McQuinn, Christopher, Loftus, Shannon , Nordquist, Emily , Cruz‐Monserrate, Zobeida , Young, Gregory , Zhong, Xiaoling , Zimmers, Teresa A. , Ostrowski, Michael C. , Ludwig, Thomas , Bloomston, Mark , Bekaii‐Saab, Tanios , Yu, Lianbo , Lesinski, Gregory B , Bekaii-Saab, Tanios S

Mayo Clinic

Gut | October 21, 2016 | Volume: 67 | Issue: 2 | Pages: 320-332

10.1136/gutjnl-2016-311585 | PMID 27797936 Get It

Objective Limited efficacy of immune checkpoint inhibitors in pancreatic ductal adenocarcinoma (PDAC) has prompted investigation into combination therapy. We hypothesised that interleukin 6 (IL-6) blockade would modulate immunological features of PDAC and enhance the efficacy of anti-programmed death-1-ligand 1 (PD-L1) checkpoint inhibitor therapy. Design Transcription profiles and IL-6 secretion from primary patient-derived pancreatic stellate cells (PSCs) were analyzed via Nanostring and immunohistochemistry, respectively. In vivo efficacy and mechanistic studies were conducted with antibodies (Abs) targeting IL-6, PD-L1, CD4 or CD8 in subcutaneous or orthotopic models using Panc02, MT5 or KPC-luc cell lines; and the aggressive, genetically engineered PDAC model (Kras LSL−G12D , Trp53 LSL−R270H , Pdx1-cre, Brca2 F/F (KPC-Brca2 mice)). Systemic and local changes in immunophenotype were measured by flow cytometry or immunohistochemical analysis. Results PSCs (n=12) demonstrated prominent IL-6 expression, which was localised to stroma of tumours. Combined IL-6 and PD-L1 blockade elicited efficacy in mice bearing subcutaneous MT5 (p<0.02) and Panc02 tumours (p=0.046), which was accompanied by increased intratumoural effector T lymphocytes (CD62L − CD44 − ). CD8-depleting but not CD4-depleting Abs abrogated the efficacy of combined IL-6 and PD-L1 blockade in mice bearing Panc02 tumours (p=0.0016). This treatment combination also elicited significant antitumour activity in mice bearing orthotopic KPC-luc tumours and limited tumour progression in KPC-Brca2 mice (p<0.001). Histological analysis revealed increased T-cell infiltration and reduced α-smooth muscle actin cells in tumours from multiple models. Finally, IL-6 and PD-L1 blockade increased overall survival in KPC-Brca2 mice compared with isotype controls (p=0.0012). Conclusions These preclinical results indicate that targeted inhibition of IL-6 may enhance the efficacy of anti-PD-L1 in PDAC.
Radiogenomics to characterize regional genetic heterogeneity in glioblastoma
Hu, Leland , Ning, Shuluo , Eschbacher, Jennifer , Baxter, Leslie C. , Gaw, Nathan , Ranjbar, Sara , Plasencia, Jonathan D. , Dueck, Amylou C. , Peng, Sen, Smith, Kris A. , Karis, John P. , Quarles, C. Chad , Loftus, Joseph C. , Jenkins, Robert B. , Sicotte, Hugues , Kollmeyer, Thomas M. , Elmquist, William F. , Frakes, David , Swanson, Kristin R. , Tran, Nhan L. , Mitchell, J. Ross , Eschbacher, Jennifer M., Plasencia, Jonathan, Nakaji, Peter , O'Neill, Brian P, Elmquist, William, Hoxworth, Joseph M. , Sarkaria, Jann, Dueck, A. C. , Baxter, Leslie C. , Wu, Teresa , O’Neill, Brian Patrick , Sarkaria, Jann N. , Swanson, Kristin R , Li, Jing , Kollmeyer, Thomas , Tran, Nhan L

Mayo Clinic

Neuro-Oncology | August 9, 2016 | Volume: 19 | Issue: 1 | Pages: 128-137

10.1093/neuonc/now135 | PMID 27502248 Get It

AbstractBackgroundGlioblastoma (GBM) exhibits profound intratumoral genetic heterogeneity. Each tumor comprises multiple genetically distinct clonal populations with different therapeutic sensitivities. This has implications for targeted therapy and genetically informed paradigms. Contrast-enhanced (CE)-MRI and conventional sampling techniques have failed to resolve this heterogeneity, particularly for nonenhancing tumor populations. This study explores the feasibility of using multiparametric MRI and texture analysis to characterize regional genetic heterogeneity throughout MRI-enhancing and nonenhancing tumor segments.MethodsWe collected multiple image-guided biopsies from primary GBM patients throughout regions of enhancement (ENH) and nonenhancing parenchyma (so called brain-around-tumor, [BAT]). For each biopsy, we analyzed DNA copy number variants for core GBM driver genes reported by The Cancer Genome Atlas. We co-registered biopsy locations with MRI and texture maps to correlate regional genetic status with spatially matched imaging measurements. We also built multivariate predictive decision-tree models for each GBM driver gene and validated accuracies using leave-one-out-cross-validation (LOOCV).ResultsWe collected 48 biopsies (13 tumors) and identified significant imaging correlations (univariate analysis) for 6 driver genes: EGFR, PDGFRA, PTEN, CDKN2A, RB1, and TP53. Predictive model accuracies (on LOOCV) varied by driver gene of interest. Highest accuracies were observed for PDGFRA (77.1%), EGFR (75%), CDKN2A (87.5%), and RB1 (87.5%), while lowest accuracy was observed in TP53 (37.5%). Models for 4 driver genes (EGFR, RB1, CDKN2A, and PTEN) showed higher accuracy in BAT samples (n = 16) compared with those from ENH segments (n = 32).ConclusionMRI and texture analysis can help characterize regional genetic heterogeneity, which offers potential diagnostic value under the paradigm of individualized oncology.
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Silverberg, Mark S. , Satsangi, Jack, Ahmad, Tariq , Arnott, Ian , Bernstein, Çharles N. , Caprilli, R., Colombel, Jean–Frédéric, Gasché, Christoph , Geboes, Karel, Jewell, Derek P., Karban, Amir, Peña, A. S. , Riddell, Robert H. , Sachar, David B., Steinhart, A. Hillary , Targan, Stephan R. , Vermeire, Séverine , Warren, Bryan F., Bernstein, Charles Noah , Brant, Steven R , Loftus, Edward V. , Schreiber, Stefan , Vermeire, Séverine

Mayo Clinic

Canadian Journal of Gastroenterology | May 17, 2016 | Volume: 19 | Issue: suppl a | Pages: 5A-36A

10.1155/2005/269076 | PMID 16151544 Get It

The discovery of a series of genetic and serological markers associated with disease susceptibility and phenotype in inflammatory bowel disease has led to the prospect of an integrated classification system involving clinical, serological and genetic parameters. The Working Party has reviewed current clinical classification systems in Crohn’s disease, ulcerative colitis and indeterminate colitis, and provided recommendations for clinical classification in practice. Progress with respect to integrating serological and genetic markers has been examined in detail, and the implications are discussed. While an integrated system is not proposed for clinical use at present, the introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Rutgeerts, Paul, Sandborn, William J. , Danese, Silvio , D’Haens, Geert , Loftus, Edward V. , Sankoh, Serap, Fox, Irving H., Parikh, Asit, Milch, Catherine , Abhyankar, Brihad, Feagan, Brian G. , Colombel, Jean‐Frédéric , Sands, Bruce E , Panaccione, Remo , Loftus, Edward V , Danese, Silvio

Mayo Clinic

Gut | April 13, 2016 | Volume: 66 | Issue: 5 | Pages: 839-851

10.1136/gutjnl-2015-311079 | PMID 26893500 Get It

Objective Vedolizumab is a gut-selective antibody to α 4 β 7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. Design Safety data (May 2009–June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received ≥1 dose of vedolizumab or placebo and were reported as exposure-adjusted incidence rates as the number of patients experiencing the event per 100 person-years (PYs) of exposure. Predictors of serious infection were assessed using a Cox proportional hazards model. Results In total, 2830 patients had 4811 PYs of vedolizumab exposure (median exposure range, 1–1977 days). No increased risk of any infection or serious infection was associated with vedolizumab exposure. Serious clostridial infections, sepsis and tuberculosis were reported infrequently (≤0.6% of patients). No cases of progressive multifocal leucoencephalopathy were observed. Independent risk factors for serious infection in UC were prior failure of a tumour necrosis factor α antagonist (HR, 1.99; 95% CIs 1.16 to 3.42; p=0.0122) and narcotic analgesic use (HR, 2.68; 95% CI 1.57 to 4.58; p=0.0003), and in CD were younger age (HR, 0.97; 95% CI 0.95 to 0.98; p<0.0001), corticosteroid (HR, 1.88; 95% CI 1.35 to 2.63; p=0.0002) or narcotic analgesic use (HR, 2.72; 95% CI 1.90 to 3.89; p<0.0001). Investigator-defined infusion-related reactions were reported for ≤5% of patients in each study. Eighteen vedolizumab-exposed patients (<1%) were diagnosed with a malignancy. Conclusions Vedolizumab has a favourable safety profile with low incidence rates of serious infections, infusion-related reactions and malignancies over an extended treatment period. Trial registration number NCT01177228, NCT00619489 , NCT00783718 , NCT00783692 , NCT01224171 , NCT00790933 .